And in February, we anticipate U.S. FDA approval of our new pen development ABCWY vaccine ... For Nucala, is the exacerbation data competitive with Dupixent and have you shown an FEV benefit ...

The green light for the pre-filled, single-use pen version of Tezspire (tezepelumab ... such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra ...

The Galaxy S25 Ultra’s S Pen lacks Bluetooth connectivity and components like a battery. Despite the missing hardware and features, the replacement S Pen costs $50, the same as the previous ...

The Samsung Galaxy S25 Ultra S Pen no longer supports Bluetooth connectivity, removing features like Air Actions. Samsung says the change was made due to low user engagement and suggests using ...

Samsung has removed Bluetooth functionality from the Galaxy S25 Ultra’s S Pen. Without Bluetooth, the S Pen does not support Air Actions and can no longer be used as a remote. The Galaxy S25 ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.